(Total Views: 88)
Posted On: 05/16/2025 8:02:56 PM
Post# of 96
If FDA approves OGM – BNGO shares will Soar!
The MD Anderson Cancer Center study on Optical Genome Mapping (OGM) is helping pave the way for new regulatory approval pathways by demonstrating OGM’s clinical utility in hematologic malignancies.
Given OGM’s ability to detect structural variants missed by traditional cytogenetics, it could qualify for expedited FDA review under the Breakthrough Devices Program.
If OGM continues to show superior sensitivity and clinical relevance, it could be incorporated into National Comprehensive Cancer Network (NCCN) guidelines, influencing oncology best practices.
As OGM gains traction, insurers may begin coverage discussions, making it more accessible for clinical applications.
Countries like China and the EU are evaluating OGM for clinical use, which could accelerate global adoption.
These pathways could fast-track OGM’s integration into clinical workflows, making it a standard-of-care tool for cancer diagnostics.
The MD Anderson Cancer Center study on Optical Genome Mapping (OGM) is helping pave the way for new regulatory approval pathways by demonstrating OGM’s clinical utility in hematologic malignancies.
Given OGM’s ability to detect structural variants missed by traditional cytogenetics, it could qualify for expedited FDA review under the Breakthrough Devices Program.
If OGM continues to show superior sensitivity and clinical relevance, it could be incorporated into National Comprehensive Cancer Network (NCCN) guidelines, influencing oncology best practices.
As OGM gains traction, insurers may begin coverage discussions, making it more accessible for clinical applications.
Countries like China and the EU are evaluating OGM for clinical use, which could accelerate global adoption.
These pathways could fast-track OGM’s integration into clinical workflows, making it a standard-of-care tool for cancer diagnostics.
(0)
(0)
